Off-Label Use of Atypical Antipsychotics: An Update
Summary of Benefits: Atypical Antipsychotics for Obsessive-Compulsive Disorder
Risperidone improves symptoms of obsessive-compulsive disorder when used as an adjunct to selective serotonin reuptake inhibitors (SSRIs) for patients whose symptoms are refractory to treatment. The strength of evidence in support of this finding is moderate. Olanzapine and risperidone are similar in effect for augmenting SSRIs. The strength of evidence in support of this finding is low.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | obsessive-compulsive | OCD | SSRI | SNRI | risperidone | quetiapine | risperidone | ziprasidone | clomipramine | olanzapine
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.